Nexalin Technology, Inc. Common Stock (NXL) is a publicly traded Healthcare sector company. As of May 19, 2026, NXL trades at $0.33 with a market cap of $7.05M and a P/E ratio of -0.67. NXL moved -0.28% today. Year to date, NXL is -44.30%; over the trailing twelve months it is -74.45%. Its 52-week range spans $0.31 to $4.49. Analyst consensus is buy with an average price target of $2.00. Rallies surfaces NXL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nexalin Acquires AI Platform for $1.3M to Support 160-Patient Trial: Nexalin acquired PONM, the AI-integrated digital health platform behind HALO Clarity and NeuroCare, for $1.3 million in stock to secure exclusive rights over remote monitoring, clinical-data capture and virtual-clinic infrastructure. The platform, deployed at UCSD, will support data workflows for a 160-participant FDA pivotal insomnia trial starting Q2 2026.
| Metric | Value |
|---|---|
| Price | $0.33 |
| Market Cap | $7.05M |
| P/E Ratio | -0.67 |
| EPS | $-0.47 |
| Dividend Yield | 0.31% |
| 52-Week High | $4.49 |
| 52-Week Low | $0.31 |
| Volume | 668.98K |
| Avg Volume | 0 |
| Revenue (TTM) | $275.58K |
| Net Income | $-8.33M |
| Gross Margin | 81.99% |
1 analysts cover NXL: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.00.